GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CollPlant Biotechnologies Ltd (NAS:CLGN) » Definitions » 3-Year RORE %

CLGN (CollPlant Biotechnologies) 3-Year RORE % : 0.00% (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is CollPlant Biotechnologies 3-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. CollPlant Biotechnologies's 3-Year RORE % for the quarter that ended in Sep. 2024 was 0.00%.

The industry rank for CollPlant Biotechnologies's 3-Year RORE % or its related term are showing as below:

CLGN's 3-Year RORE % is not ranked *
in the Biotechnology industry.
Industry Median: -9.19
* Ranked among companies with meaningful 3-Year RORE % only.

CollPlant Biotechnologies 3-Year RORE % Historical Data

The historical data trend for CollPlant Biotechnologies's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CollPlant Biotechnologies 3-Year RORE % Chart

CollPlant Biotechnologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 87.78 16.70 -66.56 26.69 23.68

CollPlant Biotechnologies Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.05 23.68 -18.70 3.06 -

Competitive Comparison of CollPlant Biotechnologies's 3-Year RORE %

For the Biotechnology subindustry, CollPlant Biotechnologies's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CollPlant Biotechnologies's 3-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CollPlant Biotechnologies's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where CollPlant Biotechnologies's 3-Year RORE % falls into.



CollPlant Biotechnologies 3-Year RORE % Calculation

CollPlant Biotechnologies's 3-Year RORE % for the quarter that ended in Sep. 2024 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -1.54--1.54 )/( -3.69-0 )
=0/-3.69
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Sep. 2024 and 3-year before.


CollPlant Biotechnologies  (NAS:CLGN) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


CollPlant Biotechnologies 3-Year RORE % Related Terms

Thank you for viewing the detailed overview of CollPlant Biotechnologies's 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


CollPlant Biotechnologies Business Description

Traded in Other Exchanges
N/A
Address
4 Oppenheimer Street, P.O. Box 4132, Weizmann Science Park, Rehovot, ISR, 7670104
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.